Wockhardt just pulled a full-on pharma soap opera this quarter — bankruptcy filings, miracle antibiotics, and a profit resurrection that would make even Ram Gopal Varma’s scripts jealous.
For Q2 FY26, the company reported revenue of ₹782 crore and a PBT of ₹91 crore, compared to just ₹16 crore loss last year — that’s a YoY profit jump of 455% (no typo). PAT came in at ₹82 crore, marking the first real profit sprint in years. The operating profit margin soared to 23%, thanks to a cocktail of lower costs, new launches, and good old financial engineering.
Stock’s current price stands at ₹1,415, giving Wockhardt a market cap of ₹22,995 crore. It trades at an eye-watering P/E of 419 — which in simpler words means the market expects this company to discover the next penicillin and maybe cure inflation while at it.
In the last 3 months, the stock is down ~8.5%, but up 80% over 3 years — truly the kind of rollercoaster where only brave retail investors or pharma romantics dare to sit. ROCE is 3.75%, ROE is negative, and promoter holding has shrunk to 49.1% — but hey, who needs cash when you have six drugs with USFDA QIDP status and a global antibiotic in Phase III trials?
2. Introduction
Let’s rewind. Once upon a time, Wockhardt was a mid-tier generic drug maker with ambitions bigger than its balance sheet. Then the USFDA came knocking with warning letters, import bans, and what can only be described as a karmic audit. Plants were shut, profits evaporated, and the once-proud multinational had to rely on hospitals and biosimilars to stay alive.
Fast forward to FY26, and suddenly the script looks different. Wockhardt has reinvented itself — or at least started rehearsing for it. It’s now positioning as a global anti-infective and biosimilar specialist with new molecules, like Zaynich (WCK 5222) and Miqnaf (WCK 4873), being tested across continents. These drugs have names that sound like Marvel villains but are actually next-gen antibiotics.
The company even made global headlines by completing a pivotal Phase III trial showing Zaynich’s superiority over Meropenem — a massive deal in infectious diseases. While its U.S. business has been officially sent to Chapter 7 heaven, Wockhardt is redirecting its energy (and ₹1,000 crore from a QIP in Nov 2024) into biotech, biosimilars, and India/UK/EU markets.
Think of it as the pharmaceutical version of a phoenix, except the ashes are still burning and the wings are a work in progress.
3. Business Model – WTF Do They Even Do?
Wockhardt’s business model can be summarised in four lines:
Make medicines that actually work when everything else fails.
Sell them in the UK, EU, India, and emerging markets because the US kicked them out.
Run super-specialty hospitals because someone needs to test those antibiotics.
Keep the R&D flame burning so investors still believe in the “biotech” tag.
It manufactures finished formulations, injectables, biopharmaceuticals, and topicals. The company is among the top 3 Indian generic players in the UK and No.1 in Methycobalamin (Vitamin B12) in India. Its 12 manufacturing facilities span India, the UK, Ireland, and Dubai, with two R&D centers — one in India and one in the UK — where 350 scientists and 132 drug-discovery associates are busy justifying that 3.5% R&D-to-sales ratio.
The product portfolio includes antibiotics, biosimilars (anti-diabetic segment growing 46% YoY), vaccines, and orals. Its biosimilar business is now active in Thailand, Algeria, Latin America, and Malaysia, while Zaynich and Miqnaf are leading the charge for antibiotic innovation.
So yes — it’s a full-stack pharma company, but one that’s currently reinventing itself from a generics struggler to a biotech storyteller.
4. Financials Overview
Consolidated (₹ crore)
Source table
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue
782
809
738
-3.3%
6.0%
EBITDA
178
110
72
61.8%
147%
PAT
82
-16
-108
612%
–
EPS (₹)
4.8
-1.4
-5.5
–
–
Commentary: From an EBITDA of ₹110 crore to ₹178 crore in a year, Wockhardt suddenly looks like a company that remembered profitability exists. OPM shot up to 23%, proving that antibiotics and restructuring can be more effective than any vaccine for bad margins.
But let’s not get carried away — this company once had an EPS of ₹58 (FY14) and now stands at just ₹4.8 annualised. It’s like comparing Dhoni’s prime batting form to his retirement jogs — still great to see, but not the same.
5. Valuation Discussion – Fair Value Range Only
Let’s talk numbers before emotions.
a) P/E Method: TTM EPS = -₹1.42 (negative), but Q2FY26 EPS = ₹4.8 ⇒ annualised = ₹19.2 Industry P/E (Nifty Pharma Median) ≈ 33x
→ Fair Value Range = ₹19.2 × (25x–40x) = ₹480 – ₹770 per share (educational, not advisory).
b) EV/EBITDA Method: EV = ₹24,825 crore, TTM EBITDA = ₹442 crore EV/EBITDA = 56x currently (ouch). If it normalises to 20–25x like peers, Fair Value Range ≈ ₹7,500–₹11,000 crore EV. ⇒ Per Share ≈ ₹690 – ₹1,010.
c) DCF Rough Cut (Assume 8% CAGR in FCF over 5 years, terminal growth 3%, discount rate 10%) DCF-derived fair equity value = ₹15,000–₹18,000 crore. ⇒ Per
